Table 1.
Autoantibodies and other laboratory parameters in SLE patients at randomization
| Range (mean ± SD) | Number (%) of patients with out-of-range values | |
|---|---|---|
| ANA (titer) | 0-1/20480 | 56 (93.3%) |
| C3c (g/l) | 0.43-1.39 (0.90 ± 0.25) | 32 (53.3%) |
| C4 (g/l) | 0.02-0.26 (0.13 ± 0.05) | 16 (26.7%) |
| LA | - | 11 (18.3%) |
| aCL IgG (RU/ml) | 0.68-121.56 (14.4 ± 20.3) | 20 (33.3%) |
| aCL IgM (RU/ml) | 1.62-52.93 (12.1 ± 10.6) | 26 (43.3%) |
| antiβ2GPI IgG (RU/ml) | 0.16-95.33 (3.8 ± 15.3) | 8 (13.3%) |
| antiβ2GPI IgM (RU/ml) | 0.14-21.66 (2.2 ± 3.7) | 24 (40%) |
aCL, anticardiolipin antibodies; ANA, antinuclear antibodies; antiβ2GPI, antiβ2-glycoprotein I antibodies; LA, lupus anticoagulant; SD, standard deviation; SLE, systemic lupus erythematosus.
Abnormal low levels for C3c: < 0.9 g/l, for C4: < 0.1 g/l. Cut-off value for aCL IgG: > 20 RU/ml, aCL IgM: > 30 RU/ml, antiβ2GPI IgG: > 3 RU/ml, antiβ2GPI IgM > 2.6 RU/ml.